Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 25;60(1):113–124. doi: 10.1093/rheumatology/keaa181

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Fig. 2 — Improvements in BASDAI over 52 weeks’ CZP treatment

(a) BASDAI for overall axSpA and r-axSpA and nr-axSpA subpopulations; (b) breakdown of BASDAI components for overall axSpA population. Full Analysis Set (n = 564). Observed case data. Mean CfB value across all patients with a week 52 BASDAI assessment is reported. *P <0.0001 (Student’s t test). axSpA: axial spondyloarthritis; CfB: change from baseline; CZP: certolizumab pegol; nr-axSpA: non-radiographic axSpA; r-axSpA: radiographic axSpA.